Compare iShares Russell 2000 ETF (IWM) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs ResMed Inc. — how do they compare? iShares Russell 2000 ETF trades at $302.93, while ResMed Inc. trades at $226.17 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while iShares Russell 2000 ETF pays none, and iShares Russell 2000 ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| IWM | RMD | |
|---|---|---|
52-Week High | $301.69 | $293.73 |
52-Week Low | $225.45 | $182.82 |
Market Cap | — | $32.61B |
Sector | — | Health |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM, the iShares Russell 2000 ETF tracking US small-cap stocks, trades at $302.33 with a 0.78% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. The ETF benefits from institutional preference due to its liquidity and options ecosystem, with recent news highlighting small-cap outperformance versus large caps in 2026.
Outlook remains positive as small caps lead market gains, but risks include higher volatility and competition from lower-cost alternatives. Institutional inflows and broadening market participation support further upside, though valuation concerns and economic sensitivity warrant monitoring.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
